- Home
- ANNX
ANNX
Annexon Inc.
as 05-17-2024 4:00pm EST
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 432.9M | IPO Year: | 2020 |
| Target Price: | $14.33 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $8.40 | Next Earning Date: | 05-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Annexon Inc. (ANNX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carson William H. | ANNX | Director | May 1 '24 | Buy | $4.68 | 3,200 | $14,982.40 | 6,400 | SEC Form 4 |
| Carson William H. | ANNX | Director | Apr 8 '24 | Buy | $6.07 | 3,200 | $19,411.20 | 3,200 | SEC Form 4 |
| Overdorf Michael | ANNX | EVP & CHIEF BUSINESS OFFICER | Feb 16 '24 | Sell | $5.48 | 1,951 | $10,691.48 | 85,641 | SEC Form 4 |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Feb 16 '24 | Sell | $5.51 | 2,604 | $14,348.04 | 72,471 | SEC Form 4 |
| Lew Jennifer | ANNX | EVP & CHIEF FINANCIAL OFFICER | Feb 16 '24 | Sell | $5.53 | 2,593 | $14,339.29 | 82,058 | SEC Form 4 |
| Overdorf Michael | ANNX | EVP & CHIEF BUSINESS OFFICER | Feb 12 '24 | Sell | $5.53 | 1,349 | $7,459.97 | 48,592 | SEC Form 4 |
| Love Douglas | ANNX | PRESIDENT AND CEO | Feb 12 '24 | Sell | $5.54 | 5,782 | $32,032.28 | 196,121 | SEC Form 4 |
| Lew Jennifer | ANNX | EVP & CHIEF FINANCIAL OFFICER | Feb 12 '24 | Sell | $5.54 | 1,809 | $10,021.86 | 45,651 | SEC Form 4 |
| Yednock Ted | ANNX | EVP & Chief Innovation Officer | Dec 27 '23 | Sell | $4.52 | 21,000 | $94,966.20 | 0 | SEC Form 4 |
| Satter Muneer A | ANNX | Director10% Owner | Dec 26 '23 | Buy | $2.88 | 350,000 | $1,008,000.00 | 7,406,024 | SEC Form 4 |
| Overdorf Michael | ANNX | EVP & Chief Business Officer | Jul 11 '23 | Sell | $3.84 | 978 | $3,751.71 | 45,802 | SEC Form 4 |
| Lew Jennifer | ANNX | EVP & Chief Financial Officer | Jul 11 '23 | Sell | $3.84 | 1,057 | $4,054.76 | 47,460 | SEC Form 4 |
Latest Annexon Inc. News
ANNX Breaking Stock News: Dive into ANNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
6 days ago
We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
GlobeNewswire
7 days ago
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
GlobeNewswire
11 days ago
Annexon Biosciences to Present at the Bank of America Health Care Conference
GlobeNewswire
12 days ago
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
Zacks
18 days ago
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
GlobeNewswire
19 days ago
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Zacks
25 days ago